All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Multidrug-Resistant Tuberculosis in Europe, 2010-2011

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F15%3A%230001066" target="_blank" >RIV/00064190:_____/15:#0001066 - isvavai.cz</a>

  • Result on the web

    <a href="http://wwwnc.cdc.gov/eid/article/21/3/14-1343_article" target="_blank" >http://wwwnc.cdc.gov/eid/article/21/3/14-1343_article</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3201/eid2103.141343" target="_blank" >10.3201/eid2103.141343</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Multidrug-Resistant Tuberculosis in Europe, 2010-2011

  • Original language description

    Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >= 1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fluoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FN - Epidemiology, infection diseases and clinical immunology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2015

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    EMERGING INFECTIOUS DISEASES

  • ISSN

    1080-6040

  • e-ISSN

  • Volume of the periodical

    21

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    409-416

  • UT code for WoS article

    000350269300003

  • EID of the result in the Scopus database